Bioextrax (BIOEX) Q2 2026 earnings summary

Executive summary

• Focus on commercializing bioplastics and protein/microfiber technologies from renewable resources, with licensing as the core business model.

• Signed a major license agreement in West Asia for PHBV production, with significant revenue potential.

• Entered a three-year framework agreement with a global top-3 chemical company for joint innovation in Home & Personal Care.

• Advanced several customer projects, including with a leading confectionery producer and Lantmännen.

Financial highlights

• Net sales for Q2 2026: 130 tkr (448 tkr Q2 2025); H1 2026: 374 tkr (527 tkr H1 2025).

• Operating loss for Q2 2026: -4,949 tkr (-4,446 tkr Q2 2025); H1 2026: -9,278 tkr (-8,435 tkr H1 2025).

• Net result per share Q2 2026: -0.10 SEK (-0.11); H1 2026: -0.20 SEK (-0.21).

• Cash flow for H1 2026: 3,460 tkr (-6,473 tkr H1 2025); cash position at June 30, 2026: 7,391 tkr.

• Equity per share at June 30, 2026: 0.25 SEK (0.53 SEK Dec 31, 2025); equity ratio: 82.7%.

Outlook and guidance

• Ongoing commercialization efforts with multiple potential license agreements in progress.

• Additional financing may be required if new commercial agreements are not secured in the next 12 months.

• Management is actively evaluating financing options and expects to secure necessary funding.